Analysts Set Five Prime Therapeutics Inc (FPRX) PT at $32.89

Share on StockTwits

Five Prime Therapeutics Inc (NASDAQ:FPRX) has earned a consensus rating of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $32.89.

Several brokerages have recently issued reports on FPRX. BidaskClub upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, June 27th. Raymond James began coverage on shares of Five Prime Therapeutics in a research note on Thursday, June 28th. They issued a “market perform” rating on the stock. Wells Fargo & Co dropped their target price on shares of Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. Wedbush upped their target price on shares of Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a research note on Friday, August 10th. Finally, Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP raised its holdings in shares of Five Prime Therapeutics by 361.5% during the first quarter. Quantbot Technologies LP now owns 7,347 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 5,755 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in Five Prime Therapeutics by 48.7% during the second quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 6,535 shares during the last quarter. Alambic Investment Management L.P. purchased a new stake in Five Prime Therapeutics during the second quarter valued at approximately $351,000. Fox Run Management L.L.C. purchased a new stake in Five Prime Therapeutics during the second quarter valued at approximately $379,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Five Prime Therapeutics by 17.8% during the first quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock valued at $430,000 after buying an additional 3,782 shares during the last quarter. 86.30% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ FPRX traded up $0.01 during midday trading on Wednesday, hitting $13.11. The stock had a trading volume of 4,044 shares, compared to its average volume of 429,277. The company has a market cap of $495.26 million, a PE ratio of -2.42 and a beta of 3.25. Five Prime Therapeutics has a 52 week low of $12.52 and a 52 week high of $48.87.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.30. The firm had revenue of $7.58 million for the quarter, compared to the consensus estimate of $5.87 million. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%. As a group, equities research analysts forecast that Five Prime Therapeutics will post -4.04 earnings per share for the current year.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

See Also: What is a stock buyback?

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply